Daunorubicin citrate  (Synonyms: Daunomycin(citrate); RP 13057(citrate); Rubidomycin(citrate))

Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor^[1][2][4][5].

Daunorubicin citrate (0-256 μg/mL, 30 min) inhibits DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells^[2].
Daunorubicin citrate (7 nM-1.9 μM, 72 h) shows chemosensitivity in Molt-4 cells and L3.6 cells^[3][4].
Daunorubicin citrate (0.4 μM, 48 h) induces apoptotic and necrosis in L3.6 cells^[4].
Daunorubicin citrate (0.4 μM, 120 min) induces ROS generation in L3.6 cells^[4].
Daunorubicin citrate (2 μM, 24 h) induces autophagy in K562 cells (myeloid cell line)^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Daunorubicin citrate (intravenous injection, 3 mg/kg, three times at 48 h intervals) produces cardiotoxicity and nephrotoxicity in rats^[5].
Daunorubicin citrate (intraperitoneal injection, 10 mg/kg) induces sister chromatid exchanges in mice^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

719.64

C₃₃H₃₇NO₁₇

1884557-85-0

OC(C(O)=O)(CC(O)=O)CC(O)=O.OC1=C2C([C@H](C[C@@](C(C)=O)(O)C2)O[C@@]3([H])C[C@@H]([C@H](O)[C@H](C)O3)N)=C(O)C4=C1C(C5=CC=CC(OC)=C5C4=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7.  [Content Brief]

  [2]. Dano K, et al. Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res. 1972 Jun;32(6):1307-14.  [Content Brief]

  [3]. Svensson SP, et al. Melanin inhibits cytotoxic effects of Doxorubicin and Daunorubicin in MOLT 4 cells. Pigment Cell Res. 2003 Aug;16(4):351-4.  [Content Brief]

  [4]. Gervasoni JE Jr, et al. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and Daunorubicin by induction of both necrosis and apoptosis. Anticancer Res. 2004 Sep-Oct;24(5A):2617-26. h  [Content Brief]

  [5]. Arozal W, et al. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions. Toxicology. 2011 Jan 11;279(1-3):91-9.  [Content Brief]

  [6]. Emeline Bollaert, et al. MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin. Int J Mol Sci. 2021 May 13;22(10):5153.  [Content Brief]

  [7]. Cheng Wu, et al. Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production. Eur J Pharm Sci. 2021 Dec 1;167:106013.  [Content Brief]